Description:
Genova Diagnostics Bone Reabsorption Assessment is a simple, direct urinary assay of pyridinium crosslinks and deoxypyridinoline, useful in identifying current rate of bone loss, lytic bone disease, and efficacy of bone support therapies. Simple sample you collect at home and send to the lab. Doctors order provided. You receive the results. Not Available to New York Residents.

Advantages of Urinary Bone Resorption Testing:
• Biochemical markers are convenient and inexpensive dynamic measures of bone turnover.
• Biomechanical markers provide immediate information on the rate of bone loss, thus
helping to predict future losses.
• Static markers of bone mass, such as photon absorptiometry (bone scans), help to
diagnose osteoporosis by establishing the amount of bone that has already been lost.
They do not provide data on the rate of loss.
• Bone scans, unlike biochemical markers, are inconvenient for regular monitoring of
therapies due to invasiveness and expense.

The Bone Resorption Assessment from Genova Laboratory can improve the quality of life for women. This test: Identifies elevated levels of bone loss before excessive damage has occurred.Enables regular testing of women for resorption rates allowing treatment intervention at its most effective-before bone loss has occurred. Monitors the effectiveness of calcium supplementation to slow bone loss and rebuild bone.

Presence in the urine of higher than normal amounts of PYD and DPD indicate a rapid rate
of bone loss.
Crosslink excretion is greatly increased in patients with osteoporosis, as well as in a number
of other conditions. These include Paget’s disease, primary hyperparathyroidism and
osteomalacia. Measurement of PYD crosslinks has also proven useful in arthritic diseases,
connective tissue disorders, cancer metastasis and alcoholic bone disease.